MX2020010144A - Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38). - Google Patents
Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38).Info
- Publication number
- MX2020010144A MX2020010144A MX2020010144A MX2020010144A MX2020010144A MX 2020010144 A MX2020010144 A MX 2020010144A MX 2020010144 A MX2020010144 A MX 2020010144A MX 2020010144 A MX2020010144 A MX 2020010144A MX 2020010144 A MX2020010144 A MX 2020010144A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- subcutaneous dosing
- methods
- cancers
- dosage forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649489P | 2018-03-28 | 2018-03-28 | |
| PCT/IB2019/000314 WO2019186273A1 (en) | 2018-03-28 | 2019-03-27 | Subcutaneous dosing of anti-cd38 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010144A true MX2020010144A (es) | 2020-12-07 |
Family
ID=66647425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010144A MX2020010144A (es) | 2018-03-28 | 2019-03-27 | Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38). |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210047427A1 (enExample) |
| EP (1) | EP3774915A1 (enExample) |
| JP (2) | JP7526099B2 (enExample) |
| KR (2) | KR20210002499A (enExample) |
| CN (1) | CN112154156A (enExample) |
| AU (2) | AU2019244478B2 (enExample) |
| BR (1) | BR112020019710A2 (enExample) |
| CA (1) | CA3095086A1 (enExample) |
| CO (1) | CO2020013252A2 (enExample) |
| MX (1) | MX2020010144A (enExample) |
| TW (2) | TW202504926A (enExample) |
| WO (1) | WO2019186273A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| EP3227338A4 (en) | 2014-12-04 | 2018-05-16 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| PL3827845T3 (pl) | 2015-11-03 | 2022-07-11 | Janssen Biotech, Inc. | Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| CA3079242A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| BR112021004130A2 (pt) * | 2018-09-11 | 2021-05-25 | Jiangsu Hengrui Medicine Co., Ltd. | anticorpo anti-cd38, fragmento de ligação ao antígeno do mesmo, e uso farmacêutico |
| JP2022512722A (ja) * | 2018-10-17 | 2022-02-07 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体の皮下投与を提供する方法 |
| KR20230010659A (ko) * | 2020-05-15 | 2023-01-19 | 다케다 야쿠힌 고교 가부시키가이샤 | Sumo-활성화 효소 억제제 및 항-cd38 항체의 투여 |
| WO2023010031A1 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers |
| WO2023045859A1 (zh) * | 2021-09-23 | 2023-03-30 | 非同（成都）生物科技有限公司 | Cd38单克隆抗体及其应用 |
| WO2024131849A1 (zh) * | 2022-12-21 | 2024-06-27 | 非同（成都）生物科技有限公司 | Cd38单克隆抗体及其应用 |
| CN121127494A (zh) | 2023-01-06 | 2025-12-12 | 武田药品工业株式会社 | 用于治疗自身免疫性疾病的抗cd38抗体 |
| WO2025193746A1 (en) | 2024-03-12 | 2025-09-18 | Takeda Pharmaceutical Company Limited | Dosing regimens of anti-cd38 antibodies for treatment of subjects with immune thrombocytopenia |
| WO2025235919A1 (en) | 2024-05-09 | 2025-11-13 | Takeda Pharmaceutical Company Limited | Dosing regimens of anti-cd38 antibodies for treatment of subjects with immunoglobulin a nephropathy |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| IT1320715B1 (it) | 2000-10-19 | 2003-12-10 | Cselt Centro Studi Lab Telecom | Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7497862B2 (en) | 2001-08-03 | 2009-03-03 | Tyco Healthcare Group Lp | Tissue marking apparatus and method |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| US20070148170A1 (en) | 2005-10-03 | 2007-06-28 | Desjarlais John R | Fc Variants With Optimized Fc Receptor Binding Properties |
| EA015584B1 (ru) * | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
| AR053489A1 (es) | 2005-05-24 | 2007-05-09 | Morphosys Ag | Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| EP3063173B1 (en) * | 2013-10-31 | 2020-07-29 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
| HRP20210552T1 (hr) * | 2015-05-13 | 2021-05-14 | Morphosys Ag | Liječenje multiplog mijeloma (mm) |
| PL3827845T3 (pl) * | 2015-11-03 | 2022-07-11 | Janssen Biotech, Inc. | Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania |
| BR112019000544A2 (pt) * | 2016-07-15 | 2019-04-24 | Takeda Pharmaceutical Company Limited | métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática |
-
2019
- 2019-03-27 CA CA3095086A patent/CA3095086A1/en active Pending
- 2019-03-27 US US17/041,783 patent/US20210047427A1/en active Pending
- 2019-03-27 EP EP19726474.0A patent/EP3774915A1/en active Pending
- 2019-03-27 AU AU2019244478A patent/AU2019244478B2/en active Active
- 2019-03-27 BR BR112020019710-6A patent/BR112020019710A2/pt unknown
- 2019-03-27 MX MX2020010144A patent/MX2020010144A/es unknown
- 2019-03-27 KR KR1020207030604A patent/KR20210002499A/ko not_active Ceased
- 2019-03-27 KR KR1020257024758A patent/KR20250117714A/ko active Pending
- 2019-03-27 CN CN201980032101.8A patent/CN112154156A/zh active Pending
- 2019-03-27 WO PCT/IB2019/000314 patent/WO2019186273A1/en not_active Ceased
- 2019-03-27 JP JP2020551797A patent/JP7526099B2/ja active Active
- 2019-03-28 TW TW113121338A patent/TW202504926A/zh unknown
- 2019-03-28 TW TW108110990A patent/TWI847979B/zh active
-
2020
- 2020-10-22 CO CONC2020/0013252A patent/CO2020013252A2/es unknown
-
2023
- 2023-12-25 JP JP2023218600A patent/JP2024045121A/ja active Pending
-
2025
- 2025-10-29 AU AU2025259859A patent/AU2025259859A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210047427A1 (en) | 2021-02-18 |
| TW202504926A (zh) | 2025-02-01 |
| AU2019244478B2 (en) | 2025-11-06 |
| KR20250117714A (ko) | 2025-08-05 |
| AU2019244478A1 (en) | 2020-11-12 |
| CN112154156A (zh) | 2020-12-29 |
| JP2024045121A (ja) | 2024-04-02 |
| JP2021519295A (ja) | 2021-08-10 |
| WO2019186273A1 (en) | 2019-10-03 |
| EP3774915A1 (en) | 2021-02-17 |
| TWI847979B (zh) | 2024-07-11 |
| TW202003566A (zh) | 2020-01-16 |
| WO2019186273A4 (en) | 2019-12-19 |
| RU2020135062A3 (enExample) | 2022-04-28 |
| AU2025259859A1 (en) | 2025-11-27 |
| BR112020019710A2 (pt) | 2021-01-26 |
| CO2020013252A2 (es) | 2020-11-10 |
| CA3095086A1 (en) | 2019-10-03 |
| JP7526099B2 (ja) | 2024-07-31 |
| RU2020135062A (ru) | 2022-04-28 |
| KR20210002499A (ko) | 2021-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020013252A2 (es) | Dosificación subcutánea de anticuerpos anti-cd38 | |
| CO2020008561A2 (es) | Dosificación subcutánea de anticuerpos anti-cd38 | |
| MX2020010458A (es) | Conjugados de camptotecina-peptido. | |
| MX2020008977A (es) | Formulaciones de anticuerpos de her2 subcutaneas. | |
| CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| EA202091134A1 (ru) | Экзосомы для иммуноонкологической и противовоспалительной терапии | |
| UY38236A (es) | COMBINACIONES FARMACÉUTICAS QUE CONTIENEN EL ANTICUERPO ANTI-CD38, ASOCIADO CON LOS ANTICUERPOS BIOESPECÍFICOS BCMAxCD3 O GPRC5DxCD3 O CD19xCD3 | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| EA201890530A1 (ru) | Конъюгаты антитела к dll3 и лекарственного средства и способы их применения | |
| MX2019004692A (es) | Anticuerpos 4-1bb anti-humano y usos de los mismos. | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| DOP2018000026A (es) | Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes | |
| EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
| EA201891399A1 (ru) | Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний | |
| EA201792300A1 (ru) | Комбинации иммуноконъюгата к cd37 и антитела к cd20 | |
| ZA202103867B (en) | Tubulysins and protein-tubulysin conjugates | |
| EA202092302A1 (ru) | Антитела к trem-1 и их применения | |
| EA201892284A1 (ru) | Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| EA201990370A1 (ru) | Терапия рака, связанная с crebbp | |
| EA202192488A1 (ru) | Антитела против tsg-6 и их применения |